PLAVIX has real-world experience with more than 70 million prescriptions worldwide23

About PLAVIX

Find out how PLAVIX works to protect your patients against the threat of future atherothrombotic events.18

Tools for Your Practice

Professional tools and materials are provided to aid you in assessing and treating your patients.

Clinical Trials

Plavix was studied in clinical trials involving a broad population of more than 81,000 patients that were at risk for future atherothrombotic events.

More than 20 million Americans with symptomatic atherothrombosis face ongoing risk of future myocardial infarction (MI), ischemic stroke, or death. PLAVIX (clopidogrel bisulfate) is therapy that features:18

  • Proven efficacy in a broad range of patients as demonstrated in 4 large clinical trials involving more than 81,000 patients24
  • Well-established safety and tolerability profile24
  • Supported by Multiple Class 1 Guideline recommendations for ACS, ischemic stroke and PAD24
Indications
Plavix® (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows:

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
–
For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined end point of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.

Acute Coronary Syndrome
–
For patients with non–ST-segment elevation acute coronary syndrome (unstable angina/non–Q-wave MI), including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined end point of cardiovascular death, MI, or stroke as well as the rate of a combined end point of cardiovascular death, MI, stroke, or refractory ischemia.

–
For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined end point of death, reinfarction, or stroke. This benefit is not known to pertain to patients who receive primary angioplasty.
Important Risk Information18
–
PLAVIX is contraindicated in patients with active pathologic bleeding such as peptic ulcer or intracranial hemorrhage. PLAVIX should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or coadministration with NSAIDs or warfarin. (See CONTRAINDICATIONS and PRECAUTIONS.*)

–
The rates of major and minor bleeding were higher in patients treated with PLAVIX plus aspirin compared with placebo
plus aspirin in clinical trials. (See ADVERSE REACTIONS.*)

–
As part of the worldwide post-marketing experience with PLAVIX, there have been cases of reported thrombotic thrombocytopenic purpura (TTP), some with fatal outcome. TTP has been reported rarely following use of PLAVIX, sometimes after a short exposure (<2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment including plasmapheresis (plasma exchange). (See WARNINGS.*)

–
In clinical trials, the most common clinically important side effects were pruritus, purpura, diarrhea, and rash; infrequent events included intracranial hemorrhage (0.4%) and severe neutropenia (0.05%). (See ADVERSE REACTIONS.*)